A Randomized, Controlled, Open-Label, Multi- Center, Parallel-Group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Subcutaneously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Methoxy polyethylene glycol-epoetin beta (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Roche
Most Recent Events
- 29 Apr 2016 New trial record